Skip to main content

Table 1 Clinicopathological characteristics of overall stage IB1-IIA2 cervical cancer patients with or without para-aortic lymphadenectomy

From: Comparison of survival outcomes with or without Para-aortic lymphadenectomy in surgical patients with stage IB1-IIA2 cervical cancer in China from 2004 to 2016

Variables

Unmatched

Matched

PALN unresected

(n = 8445,%)

PALN

Resected

(n = 357,%)

P-value

PALN unresected

(n = 1385,%)

PALN

Resected

(n = 353,%)

P-value

Age (years)

48.31 ± 9.737

47.77 ± 9.436

0.310

48.48 ± 9.603

47.75 ± 9.353

0.202

FIGO stage

  

0.072

  

0.925

 IB1

4779 (56.6%)

201 (56.3%)

 

740 (53.4%)

200 (56.7%)

 

 IB2

885 (10.5%)

52 (14.6%)

 

209 (15.1%)

50 (14.2%)

 

 IIA1

1898 (22.5%)

71 (19.9%)

 

308 (22.2%)

71 (20.1%)

 

 IIA2

613 (7.3%)

28 (7.8%)

 

105 (7.6%)

27 (7.6%)

 

 IB

123 (1.5%)

2 (0.6%)

 

9 (0.6%)

2 (0.6%)

 

 IIA

147 (1.7%)

3 (0.8%)

 

14 (1.0%)

3 (0.8%)

 

Tumour size

  

0.018

  

0.886

  ≤ 4 cm

6677 (79.1%)

272 (76.2%)

 

1048 (75.7%)

271 (76.8%)

 

  > 4 cm

1498 (17.7%)

80 (22.4%)

 

314 (22.7%)

77 (21.8%)

 

 Unknown

270 (3.2%)

5 (1.4%)

 

23 (1.7%)

5 (1.4%)

 

Histological type

  

< 0.001

  

0.498

 SCC

7587 (89.8%)

289 (81.0%)

 

1154 (83.3%)

287 (81.3%)

 

 AC

656 (7.8%)

52 (14.6%)

 

168 (12.1%)

51 (14.4%)

 

 SAC

202 (2.4%)

16 (4.5%)

 

63 (4.5%)

15 (4.2%)

 

Parametrial

  

< 0.001

  

0.634

 Negative

8307 (98.4%)

338 (94.7%)

 

1330 (96.0%)

337 (95.5%)

 

 Positive

138 (1.6%)

19 (5.3%)

 

55 (4.0%)

16 (4.5%)

 

Vaginal margin

  

0.009

  

0.375

 Negative

8250 (97.7%)

341 (95.5%)

 

1343 (97.0%)

339 (96.0%)

 

 Positive

195 (2.3%)

16 (4.5%)

 

42 (3.0%)

14 (4.0%)

 

LVSI

  

< 0.001

  

0.979

 Negative

6887 (81.6%)

262 (73.4%)

 

1025 (74.0%)

261 (73.9%)

 

 Positive

1558 (18.4%)

95 (26.6%)

 

360 (26.0%)

92 (26.1%)

 

Cervical invasion

  

0.001

  

0.898

  ≤ 1/2

3289 (38.9%)

108 (30.3%)

 

415 (30.0%)

108 (30.6%)

 

  > 1/2

4598 (54.4%)

230 (64.4%)

 

902 (65.1%)

226 (64.0%)

 

 Unknown

558 (6.6%)

19 (5.3%)

 

68 (4.9%)

19 (5.4%)

 

POAT

  

0.375

  

0.903

 Standard

4619 (54.7%)

207 (58.0%)

 

811 (58.6%)

204 (57.8%)

 

 Inadequate

736 (8.7%)

35 (9.8%)

 

145 (10.5%)

34 (9.6%)

 

 Over

2927 (34.7%)

110 (30.8%)

 

407 (29.4%)

110 (31.2%)

 

 Unknown

163 (1.9%)

5 (1.4%)

 

22 (1.6%)

5 (1.4%)

 

PLN metastasis

  

< 0.001

  

0.462

 Negative

6947 (82.3%)

237 (66.4%)

 

901 (65.1%)

237 (67.1%)

 

 Positive

1498 (17.7%)

120 (33.6%)

 

484 (34.9%)

116 (32.9%)

 
  1. PALN para-aortic lymph node, PLN pelvic lymph node, FIGO International Federation of Gynaecology and Obstetrics, SCC squamous cell carcinoma, AC adenocarcinoma, SAC adenosquamous carcinoma, LVSI lymphatic vessel space, POAT postoperative adjuvant treatment